Alcon Inc. (ETR:2U3)

Germany flag Germany · Delayed Price · Currency is EUR
73.88
-0.84 (-1.12%)
At close: Jul 15, 2025, 5:30 PM CET
39.63%
Market Cap 36.73B
Revenue (ttm) 9.18B
Net Income (ttm) 1.04B
Shares Out n/a
EPS (ttm) 2.08
PE Ratio 35.44
Forward PE 26.21
Dividend 0.30 (0.40%)
Ex-Dividend Date May 13, 2025
Volume n/a
Average Volume n/a
Open 74.96
Previous Close 74.72
Day's Range 73.88 - 74.96
52-Week Range 52.91 - 86.62
Beta n/a
RSI 45.76
Earnings Date Aug 20, 2025

About Alcon

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]

Industry Ophthalmic Goods
Founded 1945
Employees 25,599
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 2U3
Full Company Profile

Financial Performance

In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.

Financial numbers in USD Financial Statements

News

Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is...

7 days ago - Wallstreet:Online

Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received ...

7 days ago - Business Wire

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for opht...

8 days ago - Wallstreet:Online

Alcon Canada Earns Global Recognition as a Top Employer

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Can...

19 days ago - Business Wire

Alcon Canada Earns Global Recognition as a Top Employer

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a rec...

19 days ago - Wallstreet:Online

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System

Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification...

20 days ago - GlobeNewsWire

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in C...

25 days ago - Wallstreet:Online

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intrao...

25 days ago - Business Wire

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (N...

6 weeks ago - Wallstreet:Online

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

6 weeks ago - Business Wire

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...

6 weeks ago - Benzinga

US FDA approves Alcon's new dry-eye drug

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

6 weeks ago - Reuters

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250526316115/en/ TRYPTYR (acoltremon ophthalmic solution) 0.003% logo Alco...

6 weeks ago - Wallstreet:Online

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.

6 weeks ago - Business Wire

Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more

The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand f...

7 weeks ago - GlobeNewsWire

American Eagle Slumps After Weak Q1 Preview, Analyst Cuts Forecasts On Demand Concerns

JP Morgan analyst Matthew R. Boss reiterated the Neutral rating on American Eagle Outfitters, Inc. (NYSE: AEO), lowering the price forecast from $10 to $9. American Eagle shares fell nearly 15% in af...

2 months ago - Benzinga

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ETCompany ParticipantsDan Cravens - Vice President, Investor RelationsDavid...

2 months ago - Seeking Alpha

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Alcon Inc (NYSE: ALC) fell sharply in today's pre-market trading as the company posted dow...

2 months ago - Benzinga

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.

2 months ago - Benzinga

Swiss eye care firm Alcon drops after earnings miss, flags tariff impact

Alcon (NYSE:ALC) shares fell 9% in premarket trading on Wednesday, after the Swiss-American pharmaceutical and medical device company missed estimates for quarterly earnings.

2 months ago - Seeking Alpha